GASTROINTESTINAL AND OTHER CANCERS RESEARCH GROUP
Publications
2003 Publications
Hawk E, Sigman CC, Kelloff G: Prevention of gastrointestinal cancers. In Gastrointestinal Oncology. (Rustgi A, ed.), 2003, Saunders, Edinburgh, pp. 205-214
Hawk E, Viner JL, Umar A, Anderson WF, Sigman C, Guyton KZ: Cancer and the cyclooxygenase enzyme - Implications for prevention and treatment. Amer J Cancer 2:27-55, 2003
Watson AJM, Hawk E, DuBois RN: Chemoprevention of colorectal cancer. In Gastrointestinal Oncology. (Rustgi A, ed.), 2003, Saunders, Edinburgh, pp. 421-428
Hawk E: COX-2 in cancer. In Ravnetrykk - Targeted Cancer Therapies, An Odyssey. (Bruland ØS, Flægstad T, eds.), 2003, Tromso University Press, Tromso, pp. 92-95
Sabichi AL, Demierre MF, Hawk ET, Lerman CE, Lippman SM: Frontiers in cancer prevention research. Cancer Res 63:5649-5655, 2003
Kelloff GJ, O'Shaughnessy JA, Gordon GB, Hawk ET, Sigman CC: Counterpoint - Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers. Cancer Epidemiol Biomarkers Prev 12:593-596, 2003
Glebov OK, Rodriguez LM, Nakahara K, Jenkins J, Cliatt J, Humbyrd C-J, DeNobile J, Soballe P, Simon R, Wright G, Lynch P, Patterson S, Lynch H, Gallinger S, Buchbinder A, Gordon G, Hawk E, Kirsch IR: Distinguishing right from left colon by the pattern of gene expression. Cancer Epi Biomark Prev 12:755-762, 2003
Patel A, Groopman JD, Umar A. DNA methylation as a cancer-specific biomarker: from molecules to populations. Ann N Y Acad Sci. 2003 Mar;983:286-97.
Verma M, Dunn BK, Ross S, Jain P, Wang W, Hayes R, Umar A. Early detection and risk assessment: proceedings and recommendations from the Workshop on Epigenetics in Cancer Prevention. Ann N Y Acad Sci. 2003 Mar;983:298-319.
Dunn BK, Verma M, Umar A. Epigenetics in cancer prevention: early detection and risk assessment: introduction. Ann N Y Acad Sci. 2003, 983:1-4.
Umar A, Viner JL, Anderson WF, and Hawk E. Development of COX inhibitors in cancer prevention and therapy. Am J Clin Oncol 2003;26(4):S48-57.
Steele VE, Hawk ET, Viner JL, and Lubet RA. Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer. Mutat Res. 2003 Feb;523-524:137-44.
Richmond E and Viner JL. Chemoprevention of skin cancer. Semin Oncol Nurs. 2003 Feb;19(1):62-9.
Fischer SM, Conti CJ, Viner JL, Aldaz CM, and Lubet RA. Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice. Carcinogenesis. 2003 May;24(5):945-52.
Hawk ET, Viner JL, and Umar A. Non-steroidal anti-inflammatory and cyclooxygenase-2-selective inhibitors in clinical cancer prevention trials. Prog Exp Tum Res. 2003;37: 210-42.
Shotland LI, Viner JL, Ondrey FG, Dobie RA, Oeffinger KC and Schwartz CL. Monitoring for ototoxicity in cancer clinical trials. Audiology Today 2003;15(4):11-13.
Linden KG, Carpenter PM, McLaren CE, Barr RJ, Hite P, Sun JD, Li KT, Viner JL, and Meyskens FL. Chemoprevention of non-melanoma skin cancer: experience with a polyphenol from green tea. Recent Results Cancer Res. 2003;163: 165-71.
Hawk ET and Viner JL. Aspirin: still learning about the wonder drug. Gut 2003; 52(11): 1535-36.
2002 Publications
Viner J, Lawrence J, Richmond E, Hawk E. Cancer chemoprevention. In Cancer Handbook. MacMillan Publishers, Hampshire; chapter 90. (Alison MR, Weinberg R, Shay J, Liotta L, eds.), 2002.
Anderson WF, Umar A, Viner JL, Hawk ET. The role of cyclooxygenase inhibitors in cancer prevention. Curr Pharm Des 8:1035-62, 2002.
[Abstract on PubMed]
Chu KC, Anderson WF. Rates for breast cancer characteristics by estrogen and progesterone receptor status in the major racial/ethnic groups. Breast Ca Res & Treatment 74:199-211, 2002.
Phillips RKS, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP, et al: A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase-2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50:857-860, 2002.
[Abstract on PubMed]
Umar A, Viner JL, Hawk E. The future of colorectal cancer prevention. Ann NY Acad Sci 952:88-108, 2002.
[Abstract on PubMed]
Umar A, Viner JL, Richmond E, Anderson WF, Hawk E. Chemoprevention of colorectal carcinogenesis. Int J Clin Oncol 7:2-26, 2002.
[Abstract on PubMed]
Hawk ET, Viner JL, Dannenberg AJ, DuBois RN. COX-2 in cancer - a player that's defining the rules. (Editorial) J Natl Cancer Inst 94:545-546, 2002.
[Abstract on PubMed]
2001 Publications
Anderson WF, Chu KC, Chatterjee N, Brawley O, Brinton LA.Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database. J Clin Oncol. 2001 Jan 1;19(1):18-27
[Abstract on PubMed]
Anderson WF, Chu KC, Chatterjee N et al. Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the Surveillance, Epidemiology and End Results database. J Clin Oncol 19:18-27, 2001.
[Abstract on PubMed]
Anderson WF, Hawk E, Berg CD. Secondary chemoprevention of upper aerodigestive tract tumors. Semin Oncol 2001;28:106-20.
[Abstract on PubMed]
Canto MT, Anderson WF, Brawley OW: Geographic variation in breast cancer mortality for white and black women: 1986-1995. CA-A Cancer Journal For Clinicians 51:367-370, 2001.
[Abstract on PubMed]
Chu KC, Anderson WF, Fritz A, et al. Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups. Cancer 92:37-45, 2001.
[Abstract on PubMed]
Dimitrov NV, Leece CM, Seymour EM, Bermink M, Gardiner J, Tompkins ER, Hawk E, Nashawaty M, Crowell J, Bennett JL: Oltipraz concentrations in plasma, buccal mucosa cells, and lipids - pharmacological studies. Cancer Epi Biomark Prev 10:201-208, 2001.
[Abstract on PubMed]
Hawk E, Viner JL: Chemoprevention in ulcerative colitis - narrowing the gap between clinical practice and research. Annals Int Med 134:158-160, 2001.
[Abstract on PubMed]
Hawk ET, Viner JL, Anderson BF: Development of COX inhibitors as cancer chemopreventives. ASCO Educational Book pp.28-37, Spring, 2001.
Kelloff GJ, Sigman CC, Hawk ET, Johnson KM, Crowell JA, Guyton KZ: Surrogate end-point biomarkers in chemopreventive drug development. IARC Sci Publ 154:13-26, 2001.
[Abstract on PubMed]
Shotland LI, Ondrey FG, Mayo KA, Viner JL. Recommendations for cancer prevention trials using potentially ototoxic test agents. J Clin Oncol 19:1658-63, 2001.
[Abstract on PubMed]
2000 Publications
Anderson WF, Reeves JE, Elias A, Berkel H.: Outcome of patients with metastatic breast carcinoma treated at a private medical oncology clinic. Cancer 66(1):95-107, 2000
[Abstract on PubMed]
Marshall JL, Hoyer RJ, Toomey MA, Faraguna K, Chang P, Richmond E, et al: Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 18:3964-73, 2000
[Abstract on PubMed]
Kelloff GJ, Sigman CC, Hawk ET, Johnson KM, Crowell JA, Guyton KZ. Surrogate end-point biomarkers in chemopreventive drug development. IARC Sci Publ. 2001;154:13-26.
[Abstract on PubMed]
Anderson WF, Hawk E, Berg CD. Secondary chemoprevention of upper aerodigestive tract tumors. Semin Oncol. 2001 Feb;28(1):106-20.
[Abstract on PubMed]
Hawk ET, Viner JL.Chemoprevention in ulcerative colitis: narrowing the gap between clinical practice and research. Ann Intern Med. 2001 Jan 16;134(2):158-60.
[Abstract on PubMed]
Hawk E, Lippman S: Primary cancer prevention studies. Hematol Oncol Clin North Am 14:809-830, 2000
[Abstract on PubMed]
Heath E, Limburg P, Hawk E, Forastiere A: Adenocarcinoma of the esophagus: risk factors and prevention. Oncology 14:507-514, 2000
[Abstract on PubMed]
Hawk E, Breslow RA, Graubard B: Male pattern baldness and clinical prostate cancer in the Epidemiologic Follow-up Study of the First National Health and Nutrition Examination Survey. Cancer Epi Biomark Prev 9:523-527, 2000
[Abstract on PubMed]
Steinbach G, Lynch PM, Phillips R, Wallace M, Hawk E, Gordon G, Sherman J, et al: A randomized, double-blind placebo controlled study of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946-1952, 2000
[Abstract on PubMed]
Jacoby RF, Cole CE, Tutsch K, Newton MA, Kelloff G, Hawk E, Lubet RA: Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Cancer Res, 60:1864-1870, 2000
[Abstract on PubMed]
Steele VE, Holmes CA, Hawk ET, Kopelovich L, Lubet RA, Crowell JA, et al: Potential use of lipoxygenase inhibitors for cancer chemoprevention. Expert Opin Investig Drugs 9:2121-2138, 2000
[Abstract on PubMed]
Hawk E, Viner J, Lawrence J: Biomarkers as surrogates for cancer development. Current Oncol Reports 2:1-9, 2000
[Abstract on PubMed]
Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Malone WA, Boone CW, Kopelovich L, Hawk ET, Lieberman R, Lawrence JA, Ali I, Viner JL, Sigman CC: Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J Nutr 130(2S Suppl):467S?471S,2000
[Abstract on PubMed]
van Stolk R, Stoner G, Hayton WL, Chan K, DeYoung B, Kresty L, Kemmenoe BH, Elson P, Rybicki L, Church J, Provencher K, McLain D, Hawk E, Fryer B, Kelloff G, Ganapathi R, Budd GT: Phase I trial of Exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with Familial Adenomatous Polyposis. Clin Cancer Res, 6:78-89, 2000
[Abstract on PubMed]
Kelloff GJ, Sigman CC, Johnson KM, Boone CW, Greenwald P, Crowell JA, Hawk ET, Doody LA: Perspectives on surrogate endpoints in the development of drugs that reduce the risk of cancer. Cancer Epi Biomark Prev 9:127-127, 2000
[Abstract on PubMed]
Watanabe Y, Haugen-Strano A, Umar A, Yamada K, Hemmi H, Kikuchi Y, Takano S, Shibata Y, Barrett JC, Kunkel TA, Koi M: Complementation of an hMSH2 defect in human colorectal carcinoma cells by human chromosome 2 transfer. Mol. Carcinog. 29:37-49, 2000
[Abstract on PubMed]
Edelmann, W, Umar, A, Yang, K., Heyer, J, Kucherlapati, M, Lia, M, Kneitz, B, Avdievich, E, Wong, E, Kunkel, TA, Lipkin, M, Crouse, G, Kolodner, R, and Kucherlapati, R: The DNA mismatch repair gene MSH3 is cooperating in tumor suppression. Cancer Research. 60:803-807, 2000
[Abstract on PubMed]
Shinohara H, Fan D, Ozawa S, Yano S, van Arsdell M, Viner JL, Beers R, Pastan I, and IJ Fidler: Site specific expression of transferrin receptor by human colon cancer cells directly correlates with eradication by antitransferrin recombinant immunotoxin. Int J Oncol 17:643-651, 2000
[Abstract on PubMed]
Shotland LI, Ondrey FG, Mayo KA, Viner JL. Recommendations for cancer prevention trials using potentially ototoxic test agents. J Clin Oncol. 2001 Mar 15;19(6):1658-63.
[Abstract on PubMed]
Hassan R, Viner JL, Wang QC, Margulies I, Kreitman RJ, and I Pastan: Antitumor activity of K1LysPE38QQR, an immunotoxin that targets mesothelin, a cell-surface antigen overexpressed in ovarian cancer and mesothelioma. J Immunotherapy 23(4):473-479, 2000
[Abstract on PubMed]
